Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value

JAMA Cardiol. 2017 Oct 1;2(10):1066-1068. doi: 10.1001/jamacardio.2017.2911.

Authors

Daniel B Mark¹, Ilana Richman², Mark A Hlatky³

Affiliations

¹ Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
² Yale University School of Medicine, New Haven, Connecticut.
³ Stanford University School of Medicine, Stanford, California.

PMID: 28832860
DOI: 10.1001/jamacardio.2017.2911

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cardiovascular Diseases*
Cholesterol, LDL
Cost-Benefit Analysis
Humans
Proprotein Convertases
Subtilisins

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cholesterol, LDL
Proprotein Convertases
Subtilisins
evolocumab